Project description
Cancer stem cell dynamics in BRCA2-deficient breast cancer
Heterozygous germline mutations in the breast cancer susceptibility genes (BRCA) 1 or 2 predispose to breast, ovarian, pancreatic and prostate cancers. Significant evidence has accumulated in recent years on vulnerabilities specific to BRCA1/2-deficient tumours leading to the development of targeted therapies including poly(ADP-ribose) polymerase (PARP) inhibitors. Recent studies suggest that BRCA2-deficient cells can acquire metastatic and tumour-initiating capacity. The EU-funded BRCAstem project intends to study the relationship between cancer stem cells (CSCs) and the response to PARP inhibitors and ionising radiation in cancer cell lines and patient-derived xenografts lacking BRCA2. This study will uncover the mechanisms driving cell plasticity in models of BRCA2 inactivation and evaluate CSC impact on the response of BRCA-mutated tumours to current targeted therapies.
Fields of science
- medical and health sciencesclinical medicineoncologyprostate cancer
- natural sciencesphysical sciencesnuclear physics
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncologybreast cancer
- natural sciencesbiological sciencesgeneticsRNA
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EF
Coordinator
OX1 2JD Oxford
United Kingdom
See on map